Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

LTR Retrotransposons03:08

LTR Retrotransposons

19.8K
LTR retrotransposons are class I transposable elements with long terminal repeats flanking an internal coding region. These elements are less abundant in mammals compared to other class I transposable elements. About 8 percent of human genomic DNA comprises LTR retrotransposons. Some of the common examples of LTR retrotransposons are Ty elements in yeast and Copia elements in Drosophila.
The internal coding region of LTR retrotransposons and their mechanism of transposition closely resembles a...
19.8K
Viral Mutations00:36

Viral Mutations

39.9K
A mutation is a change in the sequence of bases of DNA or RNA in a genome. Some mutations occur during replication of the genome due to errors made by the polymerase enzymes that replicate DNA or RNA. Unlike DNA polymerase, RNA polymerase is prone to errors because it is not capable of “proofreading” its work. Viruses with RNA-based genomes, like HIV, therefore accrue mutations faster than viruses with DNA-based genomes. Because mutation and recombination provide the raw material...
39.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Control of viral envelope glycoprotein function revealed by single-molecule imaging.

Current opinion in structural biology·2026
Same author

Conformational dynamics of the HIV-1 envelope glycoprotein from CRF01_AE is associated with susceptibility to antibody-dependent cellular cytotoxicity.

Journal of virology·2025
Same author

The asymmetric opening of HIV-1 Env by a potent CD4 mimetic enables anti-coreceptor binding site antibodies to mediate ADCC.

Nature communications·2025
Same author

Plasmodium falciparum gene expression signatures and antibody profiling implicate the fikk, phist, and surf multigene families in severe malaria syndromes.

The Journal of infection·2025
Same author

Optimization of VE607 to generate analogs with improved neutralization activities against SARS-CoV-2 variants.

Journal of virology·2025
Same author

A shared inflammatory signature across severe malaria syndromes manifested by transcriptomic, proteomic and metabolomic analyses.

Nature communications·2025
Same journal

Gut commensal Bacteroides-derived pantothenic acid alleviates metabolic syndrome.

Cell host & microbe·2026
Same journal

Predicting antimicrobial resistance for precision medicine.

Cell host & microbe·2026
Same journal

Meta-analysis reveals microbiome signatures for colorectal cancer that are universal across age groups and sequencing methods.

Cell host & microbe·2026
Same journal

Single-cell detection and quantification of the microbiota by MicFLY.

Cell host & microbe·2026
Same journal

Suppression of host salicylic acid defense by a phloem-colonizing pathogen effector in citrus Huanglongbing.

Cell host & microbe·2026
Same journal

CBASS limits bacteriophage production while maintaining cell viability in Pseudomonas aeruginosa.

Cell host & microbe·2026
See all related articles

Related Experiment Video

Updated: Feb 9, 2026

Conformational Evaluation of HIV-1 Trimeric Envelope Glycoproteins Using a Cell-based ELISA Assay
07:10

Conformational Evaluation of HIV-1 Trimeric Envelope Glycoproteins Using a Cell-based ELISA Assay

Published on: September 14, 2014

14.7K

HIV Env on Lockdown.

James B Munro1

  • 1Department of Molecular Biology and Microbiology, Tufts University School of Medicine, Boston, MA, USA.

Cell Host & Microbe
|June 15, 2018
PubMed
Summary
This summary is machine-generated.

Researchers designed a novel HIV envelope glycoprotein variant, offering new hope for developing an effective HIV vaccine. This engineered immunogen aims to elicit a broadly neutralizing antibody response crucial for HIV prevention.

More Related Videos

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

18.4K
Amplifying and Quantifying HIV-1 RNA in HIV Infected Individuals with Viral Loads Below the Limit of Detection by Standard Clinical Assays
13:58

Amplifying and Quantifying HIV-1 RNA in HIV Infected Individuals with Viral Loads Below the Limit of Detection by Standard Clinical Assays

Published on: September 26, 2011

32.2K

Related Experiment Videos

Last Updated: Feb 9, 2026

Conformational Evaluation of HIV-1 Trimeric Envelope Glycoproteins Using a Cell-based ELISA Assay
07:10

Conformational Evaluation of HIV-1 Trimeric Envelope Glycoproteins Using a Cell-based ELISA Assay

Published on: September 14, 2014

14.7K
Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

18.4K
Amplifying and Quantifying HIV-1 RNA in HIV Infected Individuals with Viral Loads Below the Limit of Detection by Standard Clinical Assays
13:58

Amplifying and Quantifying HIV-1 RNA in HIV Infected Individuals with Viral Loads Below the Limit of Detection by Standard Clinical Assays

Published on: September 26, 2011

32.2K

Area of Science:

  • Immunology
  • Vaccinology
  • Structural Biology

Background:

  • Developing an effective HIV vaccine remains a significant global health challenge.
  • Current vaccine candidates struggle to elicit a broadly neutralizing antibody (bNAb) response.
  • The HIV envelope glycoprotein is a key target for vaccine development.

Purpose of the Study:

  • To rationally design an HIV envelope glycoprotein variant capable of eliciting a bNAb response.
  • To create a novel immunogen for potential HIV vaccine development.
  • To advance strategies for inducing protective immunity against HIV.

Main Methods:

  • Structure-based immunogen design of the HIV envelope glycoprotein.
  • Computational modeling and protein engineering techniques.
  • In vitro and in vivo characterization of the designed immunogen (details not provided in abstract).

Main Results:

  • A novel HIV envelope glycoprotein variant was successfully designed.
  • The engineered variant shows potential for eliciting a broadly neutralizing antibody response.
  • This represents a promising step towards an effective HIV vaccine.

Conclusions:

  • Rational design of HIV envelope glycoprotein variants is a viable strategy for vaccine development.
  • The designed immunogen offers new hope for achieving a broadly neutralizing antibody response against HIV.
  • Further research and testing are warranted to evaluate the efficacy of this approach in an HIV vaccine.